Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.89 +1.20%

+$0.15 today

Market cap
$341.49M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.11M

Average 0.09M

LYEL Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Lyell Immunopharma, Inc.NASDAQ: LYEL

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation outflow shrinks to $0

Q1 FY2026 stock-based compensation was $0, compared with $6.02M a year earlier. Trailing-twelve-month stock-based compensation was $35.81M.

Context

  • Stock-based compensation amounted to 116191.7% of revenue in FY2025, up 61857.2 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $8.95M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$41.83M+26.2% YoY
LTMMar 2026
$35.81M+19.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+26.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
41.83M USD
Year-over-year change
+26.2%
4-year CAGR
-9.4%

Stock-Based Compensation vs competitors

How LYEL compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +19.3% is the 2nd highest of 10, against a peer median of -35.1%.
  • Stock-based compensation amounts to 115500.0% of revenue for LYEL, versus a peer median of 75.0%.
LYEL Competitors
Stock-Based Compensation for LYEL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LYELLyell Immunopharma, Inc.LTM Mar 2026$35.81M USD+19.3%—115500.0%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$33.74M USD-35.1%-23.4%—
CABACabaletta Bio, Inc.LTM Mar 2026$21.03M USD+1.0%+44.8%—
SLNSilence Therapeutics plcLTM Mar 2026$14.34M USD—-14.0%1556.3%
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$11.09M USD+34.6%+121.4%—
EDITEditas Medicine, Inc.LTM Mar 2026$9.12M USD-45.7%-30.1%23.6%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$7.15M USD-15.9%+1.9%—
GNLXGenelux CorporationLTM Mar 2026$5.84M USD+8.8%+34.5%72950.0%
AMRNAmarin Corporation plcLTM Mar 2026$3.95M USD-191.3%—1.8%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$2.88M USD-66.7%-9.8%—
ACIUAC Immune S.A.LTM Dec 2025CHF 2.68M CHF-42.8%—75.0%
Peer median (excluding LYEL) —-35.1%-3.9%75.0%

Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Depreciation & Amortization13.62M16.47M20.25M19.63M11.54M
Deferred Income Tax39.51M0000
Stock-Based Compensation62.2M047.08M33.14M41.83M
Change in Working Capital4.02M(82.02M)3.42M(3.12M)(9.89M)
Accounts Receivables00000
Inventory00000
Accounts Payables91K667K1.46M(3.23M)(2.34M)
Other Working Capital3.92M(82.68M)1.96M114K(7.56M)
Other Non-Cash Items4.62M79.11M183K130.95M80.95M
Operating Cash Flow(126.25M)(169.56M)(163.69M)(162.39M)(150.02M)
Capital Expenditures(65.5M)(24.28M)(2.69M)(464K)(780K)
Acquisitions (Net)673.47M00(31.35M)(41.2M)
Purchases of Investments(673.47M)(406.32M)(476.88M)(394.71M)(259.71M)
Sales of Investments617.4M419.05M663.61M548.94M374.68M
Other Investing Activities(673.47M)000(18.9M)
Investing Cash Flow(121.57M)(11.54M)184.05M122.42M54.1M
Debt Repayment00000
Common Stock Issued391.8M11.1M2.2M1.4M50.41M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.44M(461K)(457K)(76K)(1K)
Financing Cash Flow401.24M10.64M1.74M1.33M50.41M
Effect of Forex Changes0186K(4K)00
Net Change in Cash153.42M(170.27M)22.09M(38.64M)(45.52M)
Free Cash Flow(191.75M)(193.83M)(166.38M)(162.86M)(150.8M)

Lyell Immunopharma, Inc.

NASDAQ:LYEL

Intrinsic Alpha fair value

Locked

Current Price

$13.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.